The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...
European regulators have recommended Johnson & Johnson’s Zytiga prostate cancer drug in a key new use earlier in the disease, which could see it gain traction against Pfizer’s rival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback